We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-7.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.41B
AUM Growth
-$143M
Cap. Flow
+$78.9M
Cap. Flow %
5.61%
Top 10 Hldgs %
48.2%
Holding
246
New
54
Increased
32
Reduced
53
Closed
52

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$38M
2
FOLD
Amicus Therapeutics
FOLD
+$22M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$21.2M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.7M
5
ANIP icon
ANI Pharmaceuticals
ANIP
+$15.6M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$25.1M
2
DXCM icon
DexCom
DXCM
+$15.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$13.5M
4
ASRT
Assertio
ASRT
+$13.4M
5
CRBP icon
Corbus Pharmaceuticals
CRBP
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.84%
2 Miscellaneous 1.6%
3 Consumer Staples 0.43%
4 Consumer Discretionary 0.07%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBPO
151
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$25K ﹤0.01%
236
-13,459
-98% -$1.57M
ISEE
152
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$24K ﹤0.01%
+1,600
New +$47.5K
BMRN icon
153
BioMarin Pharmaceuticals
BMRN
$12.5B
$21K ﹤0.01%
250
– –
ARIA
154
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$19K ﹤0.01%
+1,551
New +$18.7K
WST icon
155
West Pharmaceutical
WST
$25.7B
$12K ﹤0.01%
+138
New +$10.9K
ABMD
156
DELISTED
Abiomed Inc
ABMD
$12K ﹤0.01%
109
-63,181
-100% -$7.32M
CAPR icon
157
Capricor Therapeutics
CAPR
$498M
$11K ﹤0.01%
400
– –
SUPN icon
158
Supernus Pharmaceuticals
SUPN
$2.4B
$11K ﹤0.01%
421
-244,129
-100% -$5.45M
GKOS icon
159
Glaukos
GKOS
$10.1B
$10K ﹤0.01%
300
-5,000
-94% -$171K
INGN icon
160
Inogen
INGN
$138M
$8K ﹤0.01%
125
– –
CDMO
161
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$8K ﹤0.01%
3,476
– –
ACAD icon
162
CALL
Acadia Pharmaceuticals
ACAD
$4.61B
$7K ﹤0.01%
+100,000
New +$2.65M
INNL
163
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$7K ﹤0.01%
9,433
-538,359
-98% -$2M
NEOS
164
DELISTED
Neos Therapeutics, Inc
NEOS
$6K ﹤0.01%
1,056
-329,537
-100% -$2.23M
DVAX
165
CALL
DELISTED
Dynavax Technologies
DVAX
$5K ﹤0.01%
+15,600
New +$114K
ISEE
166
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5K ﹤0.01%
220,400
-379,600
-63% -$11.3M
AVGR
167
DELISTED
Avinger, Inc. Common Stock
AVGR
– –
0
– –
LLY icon
168
CALL
Eli Lilly
LLY
$1.01T
$3K ﹤0.01%
100,000
+99,000
+9,900% +$7.37M
XBI icon
169
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$3K ﹤0.01%
+50
New +$3.09K
AORT icon
170
Artivion
AORT
$1.24B
$2K ﹤0.01%
123
– –
MRTX
171
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2K ﹤0.01%
+521
New +$2.83K
DIA icon
172
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
$45.4B
$1K ﹤0.01%
+3
New +$566
SGMO
173
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1K ﹤0.01%
272
– –
DCOY
174
Decoy Therapeutics
DCOY
$1.78M
– –
0
– –
TNGN
175
DELISTED
TENGION INC COM NEW STK (DE)
TNGN
$1K ﹤0.01%
1,826,399
– –
5 6
7
8 9

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Perceptive Advisors held 246 positions worth $1.41B, down 9.2% from $1.55B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $78.9M of net new capital in Q4 2016, opening 54 new positions and adding to 32 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $25.1M trimmed.

  • Perceptive Advisors's largest Q4 2016 buy was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q4 2016, an estimated $38M increase.
  • Perceptive Advisors's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $25.1M.
  • Perceptive Advisors fully exited DexCom in Q4 2016, selling an estimated $15.7M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.41B portfolio in Q4 2016.
  • Perceptive Advisors opened 54 new positions and closed 52 in Q4 2016.
  • Perceptive Advisors's portfolio value fell 9.2% quarter-over-quarter to $1.41B.

Based on Perceptive Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.